Abstract
Generic products must be bioequivalent to the innovator brand before they can be marketed in Australia. There are no generic formulations of drugs with a narrow therapeutic index as it would be difficult for them to meet the required standard of bioequivalence. In Australia most generic drugs are marketed with a brand name. Some generic brands are manufactured by the same company that produces the innovator brand of the drug. Although generic brands are usually cheaper the proliferation of brands may cause confusion.
Original language | English |
---|---|
Pages (from-to) | 85-87 |
Number of pages | 3 |
Journal | Australian Prescriber |
Volume | 26 |
Issue number | 4 |
DOIs |
|
Publication status | Published - 1 Aug 2003 |
Keywords
- Bioequivalence
- Drug regulation
- Pharmaceutical industry